Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033108 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
A Phase 2 study of Stargardt Disease and Macular Atrophy, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT03033108 is a Phase 2 study of Stargardt Disease and Macular Atrophy that has completed, run by Kubota Vision. The registered enrollment target is 23 participants, below the 90-participant average among 16 other Stargardt Disease trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03033108, a Phase 2 study of Stargardt Disease and Macular Atrophy, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.
Conditions Studied
Interventions
- DRUG Emixustat
Study Locations (1)
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033108
The ClinicalTrials.gov registry entry for NCT03033108 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 16 other Stargardt Disease trials with a reported enrollment target (74% lower). The listed sponsor is Kubota Vision, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which Emixustat is the first listed.
NCT03033108 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03033108 about?
NCT03033108 is a clinical study titled "Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease". This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.
What is the current status of trial NCT03033108?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-01. Estimated completion is 2017-12.
What conditions does trial NCT03033108 study?
This clinical trial studies the following conditions: Stargardt Disease, Macular Atrophy.
What interventions are being tested in trial NCT03033108?
The interventions under investigation include: Emixustat (DRUG).
Who is sponsoring clinical trial NCT03033108?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03033108 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
-
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
ACTIVE NOT RECRUITING · Phase 2
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.